Combinations of prostaglandins and brimonidine or derivatives thereof
First Claim
1. A method of treating a mammal suffering from glaucoma or ocular hypertension, comprising administering to the mammal a therapeutically effective amount of a prostaglandin and a therapeutically effective amount of an alpha adrenergic agent of formula (I) wherein each Y is independently selected from the group consisting of N, N—
- CH3, O, S and C—
R1;
R1is hydrogen, lower alkyl or oxo;
R2, R3 and R4 are independently selected from the group consisting of hydrogen, halogen, lower alkyl and lower alkenyl;
n is an integer from 1 to 3; and
a broken line beside a solid line indicates either a single or a double bond, provided that two double bonds are not on the same carbon in the case when n=1, and their pharmaceutically acceptable salts and esters as appropriate wherein said method provides neuroprotection.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention concerns combinations of alpha adrenergic agents such as brimonidine and its derivatives as represented by formula (I) below
wherein each Y is independently selected from the group consisting of N, N—CH3, O, S and C—R1; R1 is hydrogen, lower alkyl or oxo; R2, R3 and R4 are independently selected from the group consisting of hydrogen, halogen, lower alkyl and lower alkenyl; n is an integer from 1 to 3; and a broken line beside a solid line indicates either a single or a double bond with the proviso that when n=1, both bonds from Y to C—R1 cannot be double bonds,
and prostaglandins known in the art to cause lowering of intraocular pressure
which are useful in compositions, methods of treatment and articles of manufacture for the treatment of glaucoma and alleviation of elevated intraocular pressure and providing neuroprotection.
-
Citations
7 Claims
-
1. A method of treating a mammal suffering from glaucoma or ocular hypertension, comprising administering to the mammal a therapeutically effective amount of a prostaglandin and a therapeutically effective amount of an alpha adrenergic agent of formula (I)
wherein each Y is independently selected from the group consisting of N, N— - CH3, O, S and C—
R1;
R1is hydrogen, lower alkyl or oxo;
R2, R3 and R4 are independently selected from the group consisting of hydrogen, halogen, lower alkyl and lower alkenyl;
n is an integer from 1 to 3; and
a broken line beside a solid line indicates either a single or a double bond, provided that two double bonds are not on the same carbon in the case when n=1, and their pharmaceutically acceptable salts and esters as appropriate wherein said method provides neuroprotection. - View Dependent Claims (2, 3, 4, 5, 6, 7)
- CH3, O, S and C—
Specification